Notochordal Tumors: An Update on Molecular Pathology with Therapeutic Implications

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Chordoma exhibits common expression of receptor tyrosine kinases (RTKs) and downstream signaling pathway activation.
• The transcription factor brachyury (T) is vital for notochord differentiation and implicated in familial chordomas.
• Nuclear brachyury expression is a consistent marker in both chordoma and benign notochordal cell tumors.

Purpose of the Study:

• To investigate the molecular underpinnings of chordoma, focusing on RTKs and brachyury.
• To explore the therapeutic potential of targeting identified molecular pathways in chordoma treatment.

Main Methods:

• Molecular investigations analyzing gene expression and signaling pathways.
• Review of therapeutic strategies targeting molecular pathways in chordoma.

Main Results:

• Common expression of various RTKs and activation of downstream pathways contribute to chordoma growth.
• Germline duplication of the brachyury (T) gene is frequently observed in familial chordomas.
• Targeted molecular therapies have yielded partial responses or stable disease in patients with advanced chordoma.

Conclusions:

• Molecular profiling of chordoma highlights key pathways and the brachyury gene as therapeutic targets.
• Targeting RTKs and brachyury-related pathways offers a promising avenue for chordoma treatment.
• Further research into molecular agents is warranted for effective chordoma management.